Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced its participation in the World Health Expo 2026 (WHX 2026) , held from February 9–12 at the Dubai Exhibition Centre, UAE . As one of the premier global healthcare exhibitions, WHX 2026 serves as a high-impact platform for international healthcare enterprises, research institutions, and investors to explore digital health, biomedical innovation, and life sciences in the Middle East and beyond.
Insilico Medicine, in partnership with the Emirates Drug Establishment (EDE), will present its latest breakthroughs in AI-driven drug discovery at a joint booth. Interested attendees can find the team at South Hall, Booth S19J30 (Emirates Health) .
Further reinforcing its leadership in the field, Dr. Alex Aliper, Co-founder and President of Insilico Medicine , is scheduled to speak at the "Frontier Stage: Biotechnology & Life Sciences" forum. He will join a panel discussion titled "Translational Research and Innovation: From Regional to Global" on February 9 at 3:10 PM local time. Dr. Aliper, alongside regional researchers and international biotech experts, will contribute to the discussion on key topics, including how to connect local research institutions with global biotech leaders, improve translational pathways from the laboratory to the clinic, and attract international investment to regional Research & Development ecosystems.
Since February 2023, Insilico Medicine has operated an AI and quantum computing drug discovery R&D center in Abu Dhabi. As one of the largest AI-driven drug discovery hubs in the Middle East, the center is dedicated to advancing drug discovery programs and the development of Insilico’s Pharma.AI platform, while fostering cross-disciplinary innovation at the intersection of artificial intelligence and life sciences.
The R&D center has established close and in-depth collaborations with leading UAE academic institutions, including Mohamed bin Zayed University of Artificial Intelligence (MBZUAI), Khalifa University, New York University Abu Dhabi (NYU Abu Dhabi), and United Arab Emirates University. Through joint research initiatives, talent development programs, and academic exchange platforms, Insilico Medicine is actively contributing to the region’s innovation ecosystem and continues to generate research outcomes with global impact.
These strategic efforts underscore Insilico Medicine’s commitment to advancing scientific progress across the Middle East and beyond, strengthening leadership in AI-enabled biotechnology, and sustaining long-term investment in a diverse, international talent base and an open, collaborative innovative environment.
About World Health Expo Dubai (WHX Dubai)
World Health Expo Dubai (WHX Dubai), formerly known as Arab Health, is a global meeting place for the healthcare community dedicated to advancing healthcare worldwide. For more than 50 years, it has served as a key platform for professionals driving the industry forward. As part of one of the world’s largest international healthcare exhibition networks, WHX Dubai connects attendees with the people, products, and ideas shaping healthcare today. Over four days, thousands of professionals come together to build meaningful connections and deliver tangible outcomes.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com